FGEN vs. MCRB, VERV, LXRX, KRRO, TBPH, CTNM, ERAS, PGEN, ORGO, and VNDA
Should you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Seres Therapeutics (MCRB), Verve Therapeutics (VERV), Lexicon Pharmaceuticals (LXRX), Korro Bio (KRRO), Theravance Biopharma (TBPH), Contineum Therapeutics (CTNM), Erasca (ERAS), Precigen (PGEN), Organogenesis (ORGO), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "pharmaceutical preparations" industry.
Seres Therapeutics (NASDAQ:MCRB) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.
Seres Therapeutics received 182 more outperform votes than FibroGen when rated by MarketBeat users. Likewise, 72.41% of users gave Seres Therapeutics an outperform vote while only 62.25% of users gave FibroGen an outperform vote.
Seres Therapeutics has higher earnings, but lower revenue than FibroGen. Seres Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
In the previous week, Seres Therapeutics had 4 more articles in the media than FibroGen. MarketBeat recorded 10 mentions for Seres Therapeutics and 6 mentions for FibroGen. Seres Therapeutics' average media sentiment score of 0.38 beat FibroGen's score of -0.04 indicating that FibroGen is being referred to more favorably in the news media.
59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 72.7% of FibroGen shares are held by institutional investors. 5.1% of Seres Therapeutics shares are held by company insiders. Comparatively, 2.0% of FibroGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Seres Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -143.57%.
Seres Therapeutics presently has a consensus target price of $6.67, suggesting a potential upside of 827.73%. FibroGen has a consensus target price of $2.00, suggesting a potential upside of 83.49%. Given FibroGen's stronger consensus rating and higher probable upside, research analysts clearly believe Seres Therapeutics is more favorable than FibroGen.
Summary
Seres Therapeutics beats FibroGen on 13 of the 17 factors compared between the two stocks.
Get FibroGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroGen Competitors List
Related Companies and Tools
